Of the four new products it has launched in 12 months, Boehringer Ingelheim (BI ... Indeed, having worked in the respiratory field for 90 years, BI describes 2015 as a landmark year - with ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans ... Specifically for COPD, our products have been on the market for more than 40 years.

We remind investors that the privately-held Boehringer Ingelheim ... for all its inhaler products at $35 per month, also beginning in June. Boehringer’s inhaled respiratory portfolio includes ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

in addition to lowering the list prices of some of those products. But one drugmaker also withdrew two popular children’s inhalers from the market, and the alternative is in short supply. Boehringer ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

Double Antibiotics for Single Infection Problematic Repeat antibiotic prescriptions for respiratory ... Month Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory ... German partner Boehringer Ingelheim have won ...